# US 2012/0251634 A1 · Traditional chinese drug comprising danshen extracts and sanqi extracts and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251634 A1
- Document ID: US20120251634A1
- Status: Published application
- Kind: A1
- Application number: 13/516,209
- Filed: 2010-12-17
- Published: 2012-10-04
- Earliest claimed: 2009-12-17
- Assignees: Tasly Pharmaceutical Group Co., Ltd.
- Inventors: Jingyan Han; Jun Guo; Jiying Yang; Yu Zhang; Mingxia Wang; Yuying Liu
- Web page: https://patentgrep.com/patent/US20120251634A1

## CPC

- A61K 36/258: Panax (ginseng)
- A61K 9/0007: {Effervescent (A61K9/0065 takes precedence)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/4858: {Organic compounds}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention discloses a traditional Chinese drug consisting of Danshen extract and Sanqi extract, the pharmaceutical composition comprising the above traditional Chinese drug as an active component and the use thereof. The traditional Chinese drug consists of Danshen extract and Sanqi extract in a weight ratio of (2˜6):(0.5˜2). The invention further discloses the effect of the above traditional Chinese drug and the pharmaceutical composition comprising the above traditional Chinese drug as an active component for treating cardiac microcirculation disorder and myocardial damage induced by ischemia/reperfusion.

## Claims

### Claim 1

A traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of (2˜6):(0.5˜2); preferably, said traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of (1˜4):1; more preferably, said traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of 4:1.

### Claim 2 (depends on 1)

The traditional Chinese drug composition according to claim 1, wherein said Danshen extract is a water-soluble extract, preferably, the Danshen extract is Danshensu.

### Claim 3 (depends on 1)

The traditional Chinese drug composition according to claim 1, wherein said Sanqi extract is one or more selected from the group consisting of Notoginsenoside R1, Ginsenoside Rb1, Ginsenoside Re and Ginsenoside Rg1; preferably, said Sanqi extract is Notoginsenoside R1.

### Claim 4 (depends on 1)

A pharmaceutical composition comprising the traditional Chinese drug composition according to claim 1 as an active component, wherein said pharmaceutical composition comprises 0.1˜99.9 wt % of the active component, and the balanced is pharmaceutically acceptable carrier(s).

### Claim 5 (depends on 4)

The pharmaceutical composition according to claim 4, wherein said pharmaceutical composition is tablets, capsules, drop pills, granules, oral solutions, powders, pastes, pellets, pills, suppositories, dry powder inhalations, aerosols, gels, injections or lyophilized powders for injection; preferably said tablets are orally disintegrating tablets or effervescent tablets, said capsules are soft capsules.

### Claim 6 (depends on 1)

Use of the traditional Chinese drug composition according to claim 1 and a pharmaceutical composition in the preparation of a medicine for ameliorating cardiac microcirculation disorder caused by ischemia/reperfusion, wherein the pharmaceutical composition comprises, as an active component, the traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of (2˜6):(0.5˜2); preferably, said traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of (1˜4):1; more preferably, said traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of 4:1, wherein said pharmaceutical composition comprises 0.1˜99.9 wt % of the active component, and the balanced is pharmaceutically acceptable carrier(s).

### Claim 7 (depends on 1)

Use of the traditional Chinese drug composition according to claim 1 and a pharmaceutical composition in the preparation of a medicine for treating myocardial damage and/or myocardial infarction caused by ischemia/reperfusion, wherein the pharmaceutical composition comprises, as an active component, the traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of (2˜6):(0.5˜2); preferably, said traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of (1˜4):1; more preferably, said traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of 4:1, wherein said pharmaceutical composition comprises 0.1˜99.9 wt % of the active component, and the balanced is pharmaceutically acceptable carrier(s).

### Claim 8 (depends on 1)

Use of the traditional Chinese drug composition according to claim 1 and a pharmaceutical composition in the preparation of a medicine for treating myocardial damage prior to or after an interventional treatment, wherein the pharmaceutical composition comprises, as an active component, the traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of (2˜6):(0.5˜2); preferably, said traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of (1˜4):1; more preferably, said traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of 4:1, wherein said pharmaceutical composition comprises 0.1˜99.9 wt % of the active component, and the balanced is pharmaceutically acceptable carrier(s).

### Claim 9 (depends on 1)

Use of the traditional Chinese drug composition according to claim 1 and a pharmaceutical composition in the preparation of a medicine for inhibiting microcirculation disorder with albumin leakage, wherein the pharmaceutical composition comprises, as an active component, the traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of (2˜6):(0.5˜2); preferably, said traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of (1˜4):1; more preferably, said traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of 4:1, wherein said pharmaceutical composition comprises 0.1˜99.9 wt % of the active component, and the balanced is pharmaceutically acceptable carrier(s).

### Claim 10 (depends on 1)

Use of the traditional Chinese drug composition according to claim 1 and a pharmaceutical composition in the preparation of a medicine for inhibiting albumin leakage from venules, wherein the pharmaceutical composition comprises as an active component the traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of (2˜6):(0.5˜2); preferably, said traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of (1˜4):1; more preferably, said traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of 4:1, wherein said pharmaceutical composition comprises 0.1˜99.9 wt % of the active component, and the balanced is pharmaceutically acceptable carrier(s).

### Claim 11 (depends on 2)

The traditional Chinese drug composition according to claim 2, wherein said Sanqi extract is one or more selected from the group consisting of Notoginsenoside R1, Ginsenoside Rb1, Ginsenoside Re and Ginsenoside Rg1; preferably, said Sanqi extract is Notoginsenoside R1.

### Claim 12 (depends on 2)

A pharmaceutical composition comprising the traditional Chinese drug composition according to claim 2 as an active component, wherein said pharmaceutical composition comprises 0.1˜99.9 wt % of the active component, and the balanced is pharmaceutically acceptable carrier(s).

### Claim 13 (depends on 3)

A pharmaceutical composition comprising the traditional Chinese drug composition according to claim 3 as an active component, wherein said pharmaceutical composition comprises 0.1˜99.9 wt % of the active component, and the balanced is pharmaceutically acceptable carrier(s).

### Claim 14 (depends on 1)

Use of the traditional Chinese drug composition according to claim 1 and a pharmaceutical composition in the preparation of a medicine for ameliorating cardiac microcirculation disorder caused by ischemia/reperfusion, wherein the pharmaceutical composition comprising, as an active component, the traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of (2˜6):(0.5˜2); preferably, said traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of (1˜4):1; more preferably, said traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of 4:1, wherein said pharmaceutical composition comprises 0.1˜99.9 wt % of the active component, and the balanced is pharmaceutically acceptable carrier(s), and wherein said pharmaceutical composition is tablets, capsules, drop pills, granules, oral solutions, powders, pastes, pellets, pills, suppositories, dry powder inhalations, aerosols, gels, injections or lyophilized powders for injection; preferably said tablets are orally disintegrating tablets or effervescent tablets, said capsules are soft capsules.

### Claim 15 (depends on 1)

Use of the traditional Chinese drug composition according to claim 1 and a pharmaceutical composition in the preparation of a medicine for treating myocardial damage and/or myocardial infarction caused by ischemia/reperfusion, wherein the pharmaceutical composition comprises, as an active component, the traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of (2˜6):(0.5˜2); preferably, said traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of (1˜4):1; more preferably, said traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of 4:1, wherein said pharmaceutical composition comprises 0.1˜99.9 wt % of the active component, and the balanced is pharmaceutically acceptable carrier(s), and wherein said pharmaceutical composition is tablets, capsules, drop pills, granules, oral solutions, powders, pastes, pellets, pills, suppositories, dry powder inhalations, aerosols, gels, injections or lyophilized powders for injection; preferably said tablets are orally disintegrating tablets or effervescent tablets, said capsules are soft capsules.

### Claim 16 (depends on 1)

Use of the traditional Chinese drug composition according to claim 1 and a pharmaceutical composition in the preparation of a medicine for treating myocardial damage prior to or after an interventional treatment, wherein the pharmaceutical composition comprises, as an active component, the traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of (2˜6):(0.5˜2); preferably, said traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of (1˜4):1; more preferably, said traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of 4:1, wherein said pharmaceutical composition comprises 0.1˜99.9 wt % of the active component, and the balanced is pharmaceutically acceptable carrier(s), and wherein said pharmaceutical composition is tablets, capsules, drop pills, granules, oral solutions, powders, pastes, pellets, pills, suppositories, dry powder inhalations, aerosols, gels, injections or lyophilized powders for injection; preferably said tablets are orally disintegrating tablets or effervescent tablets, said capsules are soft capsules.

### Claim 17 (depends on 1)

Use of the traditional Chinese drug composition according to claim 1 and a pharmaceutical composition in the preparation of a medicine for inhibiting microcirculation disorder with albumin leakage, wherein the pharmaceutical composition comprises, as an active component, the traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of (2˜6):(0.5˜2); preferably, said traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of (1˜4):1; more preferably, said traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of 4:1, wherein said pharmaceutical composition comprises 0.1˜99.9 wt % of the active component, and the balanced is pharmaceutically acceptable carrier(s), and wherein said pharmaceutical composition is tablets, capsules, drop pills, granules, oral solutions, powders, pastes, pellets, pills, suppositories, dry powder inhalations, aerosols, gels, injections or lyophilized powders for injection; preferably said tablets are orally disintegrating tablets or effervescent tablets, said capsules are soft capsules.

### Claim 18 (depends on 1)

Use of the traditional Chinese drug composition according to claim 1 and a pharmaceutical composition in the preparation of a medicine for inhibiting albumin leakage from venules, wherein the pharmaceutical composition comprises, as an active component, the traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of (2˜6):(0.5˜2); preferably, said traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of (1˜4):1; more preferably, said traditional Chinese drug composition consisting of Danshen extract and Sanqi extract in a weight ratio of 4:1, wherein said pharmaceutical composition comprises 0.1˜99.9 wt % of the active component, and the balanced is pharmaceutically acceptable carrier(s), and wherein said pharmaceutical composition is tablets, capsules, drop pills, granules, oral solutions, powders, pastes, pellets, pills, suppositories, dry powder inhalations, aerosols, gels, injections or lyophilized powders for injection; preferably said tablets are orally disintegrating tablets or effervescent tablets, said capsules are soft capsules.
